{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:32:02Z","timestamp":1789731122315,"version":"4.0.1"},"reference-count":107,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>In this paper, the authors present a clinical picture of the diagnosis and current treatment regimens of optic pathway glioma in the pediatric population, with an emphasis on the role of an ophthalmic diagnosis in the differentiation and monitoring of lesions. Glioma is the most common optic nerve tumor in children. Material: Articles in PubMed, Scholar and Website were reviewed, taking into account current standards of management related to sporadic or NF1-related optic glioma, epidemiology, location, course of the disease, clinical manifestations, histological types of the tumor, genetic predisposition, diagnostic ophthalmic tests currently applicable in therapeutic monitoring of the tumor, neurological diagnosis, therapeutic management and prognosis. The importance of current screening recommendations, in line with standards, was emphasized. Results: Glioma occurs in children most often in the first decade of life. Initially, they may be asymptomatic, and clinically ophthalmic changes are associated with the organ of vision or with systemic changes. Gliomas associated with the NF1 mutation have a better prognosis for sporadic gliomas. Diagnosis includes radiological imaging methods\/MRI\/ophthalmology\/OCT and visual acuity log MAR assessment. The basis of treatment is clinical observation. In the case of disease progression, surgical treatment, chemotherapy and targeted therapy are used. Conclusion: Further research into novel techniques for detecting gliomas would allow for early monitoring of the disease.<\/jats:p>","DOI":"10.3390\/jcm12216709","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T11:39:04Z","timestamp":1698147544000},"page":"6709","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Optic Pathway Gliomas in Pediatric Population\u2014Current Approach in Diagnosis and Management: Literature Review"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9221-8909","authenticated-orcid":false,"given":"Monika","family":"Modrzejewska","sequence":"first","affiliation":[{"name":"II Department of Ophthalmology, Pomeranian Medical University, Al. Powsta\u0144c\u00f3w Wlkp. 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0244-3526","authenticated-orcid":false,"given":"Joanna","family":"Olejnik-Wojciechowska","sequence":"additional","affiliation":[{"name":"Scientific Students Association of Ophtalmology, II Department of Ophthalmology, Pomeranian Medical University, Szczecin Unia Lubelska 1 Street, 71-252 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1104-0029","authenticated-orcid":false,"given":"Agnieszka","family":"Roszyk","sequence":"additional","affiliation":[{"name":"Scientific Students Association of Ophtalmology, II Department of Ophthalmology, Pomeranian Medical University, Szczecin Unia Lubelska 1 Street, 71-252 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elwira","family":"Szychot","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Oncology and Paediatric Immunology, Pomeranian Medical University, 71-252 Szczecin, Poland"},{"name":"Department of Paediatric Onclogy, Great Ormond Street Hospital for Children, London WC1N 1LE, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz Dariusz","family":"Konczak","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Oncology and Paediatric Immunology, Pomeranian Medical University, 71-252 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Szemitko","sequence":"additional","affiliation":[{"name":"Department of Intervantional Radiology, Pomerian Medical University, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw W\u0142adys\u0142aw","family":"Peregud-Pogorzelski","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Oncology and Paediatric Immunology, Pomeranian Medical University, 71-252 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2020.02.002","article-title":"Immunotherapy for Glioma: Current Management and Future Application","volume":"476","author":"Xu","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/WNO.0b013e31822aef82","article-title":"Optic Pathway Gliomas","volume":"31","author":"Avery","year":"2011","journal-title":"J. Neuro-Ophthalmol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.spen.2017.04.006","article-title":"Optic Pathway Gliomas Secondary to Neurofibromatosis Type 1","volume":"24","author":"Beres","year":"2017","journal-title":"Semin. Pediatr. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/ICU.0000000000000587","article-title":"Current Treatment of Optic Nerve Gliomas","volume":"30","author":"Farazdaghi","year":"2019","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2176\/nmc.ra.2017-0081","article-title":"Pediatric Optic Pathway\/Hypothalamic Glioma","volume":"58","author":"Aihara","year":"2018","journal-title":"Neurol. Med.-Chir."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1055\/s-0040-1722634","article-title":"Optic Nerve Gliomas","volume":"82","author":"Wladis","year":"2021","journal-title":"J. Neurol. Surg. Part B Skull Base"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3171\/2017.6.PEDS17107","article-title":"Isolated Optic Nerve Gliomas: A Multicenter Historical Cohort Study","volume":"20","author":"Shofty","year":"2017","journal-title":"J. Neurosurg. Pediatr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/26895293.2022.2046180","article-title":"Optic Nerve Gliomas in Adults: A SEER-Based Study","volume":"15","author":"Lin","year":"2022","journal-title":"All Life"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/pbc.20655","article-title":"Optic Pathway Gliomas","volume":"46","author":"Jahraus","year":"2006","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/MPH.0b013e318162bd6a","article-title":"Treatment of Optic Pathway Hypothalamic Gliomas in Childhood: Experience with 18 Consecutive Cases","volume":"30","author":"Jaing","year":"2008","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Pas, C.B., Tanajura, G.H., Giampani Junior, J., and de Brito, A.G. (2022). Glioma of the Optic Nerve and Chiasm: A Case Report. Arq. Bras. Oftalmol., ahead of print.","DOI":"10.5935\/0004-2749.2021-0246"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.21164\/pomjlifesci.602","article-title":"Urokinase of plasminogen activator (uPA) in peritoneal fluid in patients with peritonitis","volume":"65","author":"Krasodomska","year":"2019","journal-title":"Pomeranian J. Life Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.pediatrneurol.2017.06.019","article-title":"Clinical Presentation and Outcome of Patients with Optic Pathway Glioma","volume":"75","author":"Rosca","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-11-0127","article-title":"Genetic Aberrations Leading to MAPK Pathway Activation Mediate Oncogene-Induced Senescence in Sporadic Pilocytic Astrocytomas","volume":"17","author":"Jacob","year":"2011","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ccell.2020.03.011","article-title":"Integrated Molecular and Clinical Analysis of 1000 Pediatric Low-Grade Gliomas","volume":"37","author":"Ryall","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_16","first-page":"750","article-title":"Pediatric Low-Grade Gliomas: Implications of the Biologic Era","volume":"19","author":"Packer","year":"2016","journal-title":"Neuro-Oncology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/neuonc\/nox141","article-title":"Pediatric Low-Grade Gliomas: Next Biologically Driven Steps","volume":"20","author":"Jones","year":"2018","journal-title":"Neuro-Oncology"},{"key":"ref_18","unstructured":"Huang, M., Patel, J., and Patel, B.C. (2023, July 01). Optic Nerve Glioma, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/32491801\/."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/neuonc\/noaa153","article-title":"NF1 Optic Pathway Glioma: Analyzing Risk Factors for Visual Outcome and Indications to Treat","volume":"23","author":"Azizi","year":"2020","journal-title":"Neuro-Oncology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(14)71206-9","article-title":"Next-Generation (Epi)Genetic Drivers of Childhood Brain Tumours and the Outlook for Targeted Therapies","volume":"16","author":"Northcott","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"x1","DOI":"10.1093\/neuonc\/nou327","article-title":"Alex\u2019s Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007\u20132011","volume":"16","author":"Ostrom","year":"2015","journal-title":"Neuro-Oncology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/pbc.24958","article-title":"Long-Term Outcome of 4040 Children Diagnosed with Pediatric Low-Grade Gliomas: An Analysis of the Surveillance Epidemiology and End Results (SEER) Database: PLGG SEER Long-Term Outcome","volume":"61","author":"Bandopadhayay","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/cncr.29907","article-title":"Clinical and Treatment Factors Determining Long-Term Outcomes for Adult Survivors of Childhood Low-Grade Glioma: A Population-Based Study","volume":"122","author":"Krishnatry","year":"2016","journal-title":"Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/nan.12013","article-title":"Outcome Analysis of Childhood Pilocytic Astrocytomas: A Retrospective Study of 148 Cases at a Single Institution: Outcome Study of Pilocytic Astrocytomas","volume":"39","author":"Colin","year":"2013","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fonc.2015.00054","article-title":"Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas","volume":"5","author":"Penman","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"10537","DOI":"10.1200\/JCO.2018.36.15_suppl.10537","article-title":"Phase 1 Trial of Trametinib Alone and in Combination with Dabrafenib in Children and Adolescents with Relapsed Solid Tumors or Neurofibromatosis Type 1 (NF1) Progressive Plexiform Neurofibromas (PN)","volume":"36","author":"Geoerger","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1002\/cam4.3910","article-title":"Trametinib Therapy for Children with Neurofibromatosis Type 1 and Life-Threatening Plexiform Neurofibroma or Treatment-Refractory Low-Grade Glioma","volume":"10","author":"Ronsley","year":"2021","journal-title":"Cancer Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11060-020-03592-8","article-title":"Trametinib for the Treatment of Recurrent\/Progressive Pediatric Low-Grade Glioma","volume":"149","author":"Manoharan","year":"2020","journal-title":"J. Neurooncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/ng.2682","article-title":"Recurrent Somatic Alterations of FGFR1 and NTRK2 in Pilocytic Astrocytoma","volume":"45","author":"Jones","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1212\/01.wnl.0000180409.78098.d7","article-title":"RAS Pathway Activation and an Oncogenic RAS Mutation in Sporadic Pilocytic Astrocytoma","volume":"65","author":"Sharma","year":"2005","journal-title":"Neurology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"i31","DOI":"10.1093\/neuonc\/noab090.126","article-title":"LGG-02. Pediatric Low-Grade Glioma Risk Stratification in the Molecular Era","volume":"23","author":"Hata","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/neuonc\/noz022","article-title":"Molecular Profiling and Targeted Therapy in Pediatric Gliomas: Review and Consensus Recommendations","volume":"21","author":"Miklja","year":"2019","journal-title":"Neuro-Oncology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e26838","DOI":"10.1002\/pbc.26838","article-title":"Neurofibromatosis Type 1 and Optic Pathway Glioma: Molecular Interplay and Therapeutic Insights","volume":"65","author":"Khatua","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/humu.22392","article-title":"NF1 Molecular Characterization and Neurofibromatosis Type I Genotype-Phenotype Correlation: The French Experience","volume":"34","author":"Sabbagh","year":"2013","journal-title":"Hum. Mutat."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"890875","DOI":"10.3389\/fsurg.2022.890875","article-title":"Rethinking the Management of Optic Pathway Gliomas: A Single Center Experience","volume":"9","author":"Cacchione","year":"2022","journal-title":"Front. Surg."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/nop\/npz033","article-title":"Neuro-Oncology Practice Clinical Debate: Targeted Therapy vs Conventional Chemotherapy in Pediatric Low-Grade Glioma","volume":"7","author":"Cooney","year":"2019","journal-title":"Neuro-Oncol. Pract."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"789856","DOI":"10.3389\/fonc.2022.789856","article-title":"Epidemiology and Survival of Patients with Optic Pathway Gliomas: A Population-Based Analysis","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jns.2019.03.028","article-title":"Characteristics, Survival and Incidence Rates and Trends of Pilocytic Astrocytoma in Children in the United States; SEER-Based Analysis","volume":"400","author":"Tabash","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"ref_39","unstructured":"Knight, J., and De Jesus, O. (2023). Pilocytic Astrocytoma, StatPearls Publishing."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00401-015-1410-7","article-title":"Pilocytic Astrocytoma: Pathology, Molecular Mechanisms and Markers","volume":"129","author":"Collins","year":"2015","journal-title":"Acta Neuropathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/onc.2013.148","article-title":"The Molecular and Cell Biology of Pediatric Low-Grade Gliomas","volume":"33","author":"Chen","year":"2014","journal-title":"Oncogene"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0883073817739509","article-title":"Optic Pathway Gliomas in Neurofibromatosis Type 1","volume":"33","author":"Campen","year":"2018","journal-title":"J. Child Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.canep.2018.04.005","article-title":"Evaluation of Racial Disparities in Pediatric Optic Pathway Glioma Incidence: Results from the Surveillance, Epidemiology, and End Results Program, 2000\u20132014","volume":"54","author":"Montenegro","year":"2018","journal-title":"Cancer Epidemiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.critrevonc.2016.05.008","article-title":"Neurofibromatosis Type 1 Associated Low Grade Gliomas: A Comparison with Sporadic Low Grade Gliomas","volume":"104","author":"Helfferich","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ejpn.2015.12.002","article-title":"Systematic MRI in NF1 Children under Six Years of Age for the Diagnosis of Optic Pathway Gliomas. Study and Outcome of a French Cohort","volume":"20","author":"Blanchard","year":"2016","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11060-017-2517-6","article-title":"Natural History of Optic Pathway Gliomas in a Cohort of Unselected Patients Affected by Neurofibromatosis 1","volume":"134","author":"Trevisson","year":"2017","journal-title":"J. Neurooncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1212\/WNL.0000000000002771","article-title":"Quantitative MRI Criteria for Optic Pathway Enlargement in Neurofibromatosis Type 1","volume":"86","author":"Avery","year":"2016","journal-title":"Neurology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1200\/JCO.2016.71.8726","article-title":"Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas","volume":"35","author":"Lassaletta","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_49","first-page":"103","article-title":"Co-Occurrence of Histone H3 K27M and BRAF V600E Mutations in Paediatric Midline Grade I Ganglioglioma","volume":"28","author":"Beccaria","year":"2017","journal-title":"Brain Pathol."},{"key":"ref_50","first-page":"42","article-title":"Prognostic role of BRAF mutation in low grade gliomas: A meta-analysis","volume":"147","author":"Zhang","year":"2020","journal-title":"World Neurosurg."},{"key":"ref_51","first-page":"vdab063","article-title":"Irradiation of Nf1 mutant mouse models of spinal plexiform neurofibromas drives pathologic progression and decreases survival","volume":"3","author":"Laurent","year":"2021","journal-title":"Neurooncol. Adv."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"i98","DOI":"10.1093\/noajnl\/vdz054","article-title":"NF1-like Optic Pathway Gliomas in Children: Clinical and Molecular Characterization  of This Specific Presentation","volume":"2","author":"Laurendeau","year":"2020","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jpeds.2015.07.001","article-title":"The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1","volume":"167","author":"Prada","year":"2015","journal-title":"J. Pediatr."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13023-018-0811-9","article-title":"Serial MRIs Provide Novel Insight into Natural History of Optic Pathway Gliomas in Patients with Neurofibromatosis 1","volume":"13","author":"Sellmer","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ana.24093","article-title":"Sex Is a Major Determinant of Neuronal Dysfunction in Neurofibromatosis Type 1: Sex Impacts Outcomes in NF1","volume":"75","author":"Brown","year":"2014","journal-title":"Ann. Neurol."},{"key":"ref_56","first-page":"4095","article-title":"Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature","volume":"36","author":"Friedrich","year":"2016","journal-title":"Anticancer. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00013414-200206000-00008","article-title":"Surgical Treatment of Brainstem Gliomas in Children","volume":"12","author":"Roonprapunt","year":"2002","journal-title":"Neurosurg. Q."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"vdac182","DOI":"10.1093\/noajnl\/vdac182","article-title":"Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment","volume":"5","author":"Tsai","year":"2023","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000445064","article-title":"Optic Pathway Gliomas: Clinical Manifestation, Treatment, and Follow-Up","volume":"51","author":"Ertiaei","year":"2016","journal-title":"Pediatr. Neurosurg."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/ICU.0000000000000370","article-title":"Optic Pathway Glioma of Childhood","volume":"28","author":"Rasool","year":"2017","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"i143","DOI":"10.1093\/neuonc\/noy059.512","article-title":"NFM-04. Initial management strategy as a discriminator of visual outcome in children presenting with neurofibromatosis type 1 and optic pathway glioma\u2014Results from a soci\u00e9t\u00e9 internationale d\u2019oncologie p\u00e9diatrique europe (siope) clinical trials workshop","volume":"20","author":"Azizi","year":"2018","journal-title":"Neuro-Oncology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/nop\/npaa031","article-title":"Regarding \u201cNeuro-Oncology Practice Clinical Debate: Targeted Therapy vs Conventional Chemotherapy in Pediatric Low-Grade Glioma\u201d","volume":"7","author":"Walker","year":"2020","journal-title":"Neuro-Oncol. Pract."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"349.e1","DOI":"10.1016\/j.jaapos.2020.07.013","article-title":"Visual Field Outcomes in Children Treated for Neurofibromatosis Type 1\u2013Associated Optic Pathway Gliomas: A Multicenter Retrospective Study","volume":"24","author":"Heidary","year":"2020","journal-title":"J. Am. Assoc. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Cassina, M., Frizziero, L., Opocher, E., Parrozzani, R., Sorrentino, U., Viscardi, E., Miglionico, G., Midena, E., Clementi, M., and Trevisson, E. (2019). Optic Pathway Glioma in Type 1 Neurofibromatosis: Review of Its Pathogenesis, Diagnostic Assessment, and Treatment Recommendations. Cancers, 11.","DOI":"10.3390\/cancers11111790"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/sj.eye.6701592","article-title":"Primary Tumours of the Optic Nerve and Its Sheath","volume":"18","author":"Miller","year":"2004","journal-title":"Eye"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3389\/fneur.2018.01102","article-title":"Use of Optical Coherence Tomog- Raphy to Detect Retinal Nerve Fiber Loss in Children with Optic Pathway Glioma","volume":"9","author":"Zahavi","year":"2018","journal-title":"Front. Neurol."},{"key":"ref_67","first-page":"6731","article-title":"Vincristine-Induced Blindness: A Case Report and Review of Literature","volume":"34","author":"Adhikari","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e1004","DOI":"10.1111\/aos.13803","article-title":"Correlation of Peripapillary Retinal Nerve Fibre Layer Thickness with Visual Acuity in Paediatric Patients Affected by Optic Pathway Glioma","volume":"96","author":"Parrozzani","year":"2018","journal-title":"Acta Ophthalmol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ajo.2012.08.010","article-title":"Normative Reference Ranges for the Retinal Nerve Fiber Layer, Macula, and Retinal Layer Thicknesses in Children","volume":"155","author":"Yanni","year":"2013","journal-title":"Am. J. Ophthalmol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"8112","DOI":"10.1167\/iovs.13-13093","article-title":"Optical Coherence Tomography in the Diagnosis of Optic Pathway Gliomas","volume":"54","author":"Parrozzani","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1212\/WNL.0000000000003402","article-title":"Optic Pathway Glioma Volume Predicts Retinal Axon Degeneration in Neurofibromatosis Type 1","volume":"87","author":"Avery","year":"2016","journal-title":"Neurology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/ana.21107","article-title":"Optic Pathway Gliomas in Neurofibromatosis-1: Controversies and Recommendations","volume":"61","author":"Listernick","year":"2007","journal-title":"Ann. Neurol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.ajo.2015.07.036","article-title":"Longitudinal Change of Circumpapillary Retinal Nerve Fiber Layer Thickness in Children with Optic Pathway Gliomas","volume":"160","author":"Avery","year":"2015","journal-title":"Am. J. Ophthalmol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"6036","DOI":"10.1167\/iovs.14-16053","article-title":"In Vivo Detection of Choroidal Abnormalities Related to NF1: Feasibility and Comparison with Standard NIH Diagnostic Criteria in Pediatric Patients","volume":"56","author":"Parrozzani","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00431-013-2145-x","article-title":"Ophthalmological Assessment of Children with Neurofibromatosis Type 1","volume":"173","author":"Alpfidan","year":"2014","journal-title":"Eur. J. Pediatr."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/IAE.0000000000001578","article-title":"Retinal Vascular Abnormalities in a Large Cohort of Patients Affected by Neurofibromatosis Type 1: A Study Using Optical Coherence Tomography Angiography","volume":"38","author":"Parrozzani","year":"2018","journal-title":"Retina"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e28401","DOI":"10.1002\/pbc.28401","article-title":"Gliomas, Germ Cell Tumors, and Craniopharyngioma","volume":"68","author":"Aridgides","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"de Lucio Delgado, A., Villegas Rubio, J.A., Ria\u00f1o-Gal\u00e1n, I., and P\u00e9rez Gord\u00f3n, J. (2023). Effect of the Use of Gnrh Analogs in Low-Grade Cerebral Glioma. Children, 10.","DOI":"10.3390\/children10010115"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40291-022-00612-3","article-title":"Glioma 2021 WHO Classification: The Superiority of NGS Over IHC in Routine Diagnostics","volume":"26","author":"Bebyn","year":"2022","journal-title":"Mol. Diagn. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1101\/gr.180612.114","article-title":"Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution","volume":"25","author":"Kim","year":"2015","journal-title":"Genome Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/jamaophthalmol.2019.4511","article-title":"SETD2 Mutation in an Aggressive Optic Nerve Glioma","volume":"138","author":"Campbell","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/WNO.0000000000000550","article-title":"Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision","volume":"37","author":"Fisher","year":"2017","journal-title":"J. Neuroophthalmol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1167\/iovs.12-11385","article-title":"Feasibility and Comparison of Visual Acuity Testing Methods in Children with Neurofibromatosis Type 1 and\/or Optic Pathway Gliomas","volume":"54","author":"Avery","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/neuonc\/not120","article-title":"Detection of Tumor Progression in Optic Pathway Glioma with and without Neurofibromatosis Type 1","volume":"15","author":"Kelly","year":"2013","journal-title":"Neuro-Oncology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e1044","DOI":"10.1111\/aos.13831","article-title":"Ophthalmological Examination in Neurofibromatosis Type 1: A Long-Term Retrospective Analysis","volume":"96","author":"Cassiman","year":"2018","journal-title":"Acta Ophthalmol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.ophtha.2015.04.038","article-title":"Study of Optimal Perimetric Testing In Children (OPTIC): Normative Visual Field Values in Children","volume":"122","author":"Patel","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/cns.12.47","article-title":"Optic Pathway Gliomas: A Review","volume":"2","author":"Fried","year":"2013","journal-title":"CNS Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1055\/a-0889-8256","article-title":"SIOP-E-BTG and GPOH guidelines for diagnosis and treatment of children and adolescents with low grade glioma","volume":"231","author":"Gnekow","year":"2019","journal-title":"Klin. Padiatr."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.3171\/FOC-07\/11\/E2","article-title":"Optic pathway gliomas: A review","volume":"23","author":"Binning","year":"2007","journal-title":"Neurosurg. Focus"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1200\/JCO.2011.36.6054","article-title":"Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report from the Children\u2019s Oncology Group","volume":"30","author":"Ater","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.2016.68.1585","article-title":"Phase II Weekly Vinblastine for Chemotherapy-Na\u00efve Children with Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study","volume":"34","author":"Lassaletta","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ijc.29711","article-title":"Single Agent Carboplatin for Pediatric Low-Grade Glioma: A Retrospective Analysis Shows Equivalent Efficacy to Multiagent Chemotherapy: Carboplatin in Pediatric Low Grade Glioma","volume":"138","author":"Dodgshun","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/cam4.1799","article-title":"Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma","volume":"8","author":"Zhukova","year":"2018","journal-title":"Cancer Med."},{"key":"ref_94","first-page":"4593","article-title":"Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1002\/cncr.28343","article-title":"Bevacizumab (BVZ)-Associated Toxicities in Children with Recurrent Central Nervous System Tumors Treated with BVZ and Irinotecan (CPT-11)","volume":"119","author":"Fangusaro","year":"2013","journal-title":"Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1001\/jamaophthalmol.2013.5819","article-title":"Marked Recovery of Vision in Children with Optic Pathway Gliomas Treated with Bevacizumab","volume":"132","author":"Avery","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e27234","DOI":"10.1002\/pbc.27234","article-title":"Single-Agent Bevacizumab in the Treatment of Recurrent or Refractory Pediatric Low-Grade Glioma: A Single Institutional Experience","volume":"65","author":"Gorsi","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/neuonc\/not154","article-title":"Efficacy of Bevacizumab plus Irinotecan in Children with Recurrent Low-Grade Gliomas\u2014A Pediatric Brain Tumor Consortium Study","volume":"16","author":"Gururangan","year":"2013","journal-title":"Neuro-Oncology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/cam4.699","article-title":"Can Metronomic Maintenance with Weekly Vinblastine Prevent Early Relapse\/Progression after Bevacizumab\u2013Irinotecan in Children with Low-Grade Glioma?","volume":"5","author":"Heng","year":"2016","journal-title":"Cancer Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/pbc.21935","article-title":"Objective Response of Multiply Recurrent Low-Grade Gliomas to Bevacizumab and Irinotecan","volume":"52","author":"Packer","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/pbc.24066","article-title":"Bevacizumab and Irinotecan in Children with Recurrent or Refractory Brain Tumors: Toxicity and Efficacy Trends","volume":"59","author":"Couec","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1097\/MPH.0000000000000371","article-title":"Confirmation of Bevacizumab Activity, and Maintenance of Efficacy in Retreatment after Subsequent Relapse, in Pediatric Low-Grade Glioma","volume":"37","author":"Kalra","year":"2015","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: A Summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/neuonc\/noac223","article-title":"A Nationwide Evaluation of Bevacizumab-Based Treatments in Pediatric Low-Grade Glioma in the UK: Safety, Efficacy, Visual Morbidity, and Outcomes","volume":"25","author":"Green","year":"2023","journal-title":"Neuro-Oncology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ijrobp.2017.07.023","article-title":"Radiation Therapy for Optic Pathway and Hypothalamic Low-Grade Gliomas in Children","volume":"99","author":"Tsang","year":"2017","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11060-020-03640-3","article-title":"Response to Trametinib Treatment in Progressive Pediatric Low-Grade Glioma Patients","volume":"149","author":"Selt","year":"2020","journal-title":"J. Neuro-Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Perreault, S., Larouche, V., Tabori, U., Hawkin, C., Lipp\u00e9, S., Ellezam, B., D\u00e9carie, J.-C., Th\u00e9oret, Y., M\u00e9tras, M.-\u00c9., and Sultan, S. (2019). A Phase 2 Study of Trametinib for Patients with Pediatric Glioma or Plexiform Neurofibroma with Refractory Tumor and Activation of the MAPK\/ERK Pathway: TRAM-01. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6442-2"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/21\/6709\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:10:46Z","timestamp":1760130646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/21\/6709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":107,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["jcm12216709"],"URL":"https:\/\/doi.org\/10.3390\/jcm12216709","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]}}}